220 related articles for article (PubMed ID: 27713772)
1. A new treatment approach - Eplerenone - in central serous chorioretinopathy - Case report.
Cioboata M; Alexandrescu C; Hopinca CA; Pienaru MC; Merticariu A; Schmitzer S
J Med Life; 2016; 9(1):92-94. PubMed ID: 27713772
[TBL] [Abstract][Full Text] [Related]
2. Clinical experience with eplerenone to treat chronic central serous chorioretinopathy.
Cakir B; Fischer F; Ehlken C; Bühler A; Stahl A; Schlunck G; Böhringer D; Agostini H; Lange C
Graefes Arch Clin Exp Ophthalmol; 2016 Nov; 254(11):2151-2157. PubMed ID: 27145785
[TBL] [Abstract][Full Text] [Related]
3. Mineralocorticoid receptor antagonism in the treatment of chronic central serous chorioretinopathy: a pilot study.
Bousquet E; Beydoun T; Zhao M; Hassan L; Offret O; Behar-Cohen F
Retina; 2013; 33(10):2096-102. PubMed ID: 23719402
[TBL] [Abstract][Full Text] [Related]
4. Systemic Mineralocorticoid Antagonists in the Treatment of Central Serous Chorioretinopathy.
Yang D; Eliott D
Semin Ophthalmol; 2017; 32(1):36-42. PubMed ID: 27929707
[TBL] [Abstract][Full Text] [Related]
5. The use of eplerenone in therapy-resistant chronic central serous chorioretinopathy.
Breukink MB; den Hollander AI; Keunen JE; Boon CJ; Hoyng CB
Acta Ophthalmol; 2014 Sep; 92(6):e488-90. PubMed ID: 24698599
[No Abstract] [Full Text] [Related]
6. CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH MINERALOCORTICOID ANTAGONISTS: A ONE-YEAR PILOT STUDY.
Ghadiali Q; Jung JJ; Yu S; Patel SN; Yannuzzi LA
Retina; 2016 Mar; 36(3):611-8. PubMed ID: 26405766
[TBL] [Abstract][Full Text] [Related]
7. A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROL PILOT STUDY OF EPLERENONE FOR THE TREATMENT OF CENTRAL SEROUS CHORIORETINOPATHY (ECSELSIOR).
Rahimy E; Pitcher JD; Hsu J; Adam MK; Shahlaee A; Samara WA; Vander JF; Kaiser RS; Chiang A; Spirn MJ; Fineman MS
Retina; 2018 May; 38(5):962-969. PubMed ID: 28426624
[TBL] [Abstract][Full Text] [Related]
8. Comparison of two mineralcorticosteroids receptor antagonists for the treatment of central serous chorioretinopathy.
Pichi F; Carrai P; Ciardella A; Behar-Cohen F; Nucci P;
Int Ophthalmol; 2017 Oct; 37(5):1115-1125. PubMed ID: 27757733
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid antagonists in the treatment of central serous chorioetinopathy: Review of the pre-clinical and clinical evidence.
Bousquet E; Zhao M; Daruich A; Behar-Cohen F
Exp Eye Res; 2019 Oct; 187():107754. PubMed ID: 31401003
[TBL] [Abstract][Full Text] [Related]
10. The use of mineralocorticoid receptor antagonists in chronic central serous chorioretinopathy.
Pociej-Marciak W; Karska-Basta I; Ozog-Baran J; Kubicka-Trzaska A; Filemonowicz-Skoczek A; Romanowska-Dixon B
Klin Oczna; 2016 Aug; 118(1):48-54. PubMed ID: 29715409
[TBL] [Abstract][Full Text] [Related]
11. SPIRONOLACTONE AS A THERAPEUTIC ALTERNATIVE FOR THE BULLOUS VARIANT OF CENTRAL SEROUS CHORIORETINOPATHY.
Ramos-Yau EC; Muñoz-Domínguez E; Contreras-Mérida SP; Valencia-Londoño LM
Retin Cases Brief Rep; 2020; 14(4):381-385. PubMed ID: 29595560
[TBL] [Abstract][Full Text] [Related]
12. [Eplerenone treatment in chronic central serous chorioretinopathy].
Sampo M; Soler V; Gascon P; Ho Wang Yin G; Hoffart L; Denis D; Matonti F
J Fr Ophtalmol; 2016 Jun; 39(6):535-42. PubMed ID: 27230892
[TBL] [Abstract][Full Text] [Related]
13. Minoxidil induced central serous Chorioretinopathy treated with oral Eplerenone - a case report.
Venkatesh R; Pereira A; Jain K; Yadav NK
BMC Ophthalmol; 2020 Jun; 20(1):219. PubMed ID: 32503484
[TBL] [Abstract][Full Text] [Related]
14. Oral eplerenone for treatment of chronic central serous chorioretinopathy: a case series.
Salz DA; Pitcher JD; Hsu J; Regillo CD; Fineman MS; Elliott KS; Vander JF; Fischer DH; Spirn MJ
Ophthalmic Surg Lasers Imaging Retina; 2015 Apr; 46(4):439-44. PubMed ID: 25970864
[TBL] [Abstract][Full Text] [Related]
15. Mineralocorticoid Receptor Antagonists in Central Serous Chorioretinopathy: A Meta-Analysis of Randomized Controlled Trials.
Wang SK; Sun P; Tandias RM; Seto BK; Arroyo JG
Ophthalmol Retina; 2019 Feb; 3(2):154-160. PubMed ID: 31014765
[TBL] [Abstract][Full Text] [Related]
16. Eplerenone for chronic central serous chorioretinopathy-a randomized controlled prospective study.
Schwartz R; Habot-Wilner Z; Martinez MR; Nutman A; Goldenberg D; Cohen S; Shulman S; Guzner-Gur H; Loewenstein A; Goldstein M
Acta Ophthalmol; 2017 Nov; 95(7):e610-e618. PubMed ID: 28653813
[TBL] [Abstract][Full Text] [Related]
17. Eplerenone in patients with chronic recurring central serous chorioretinopathy.
Leisser C; Hirnschall N; Hackl C; Plasenzotti P; Findl O
Eur J Ophthalmol; 2016 Aug; 26(5):479-84. PubMed ID: 26692062
[TBL] [Abstract][Full Text] [Related]
18. SPIRONOLACTONE FOR NONRESOLVING CENTRAL SEROUS CHORIORETINOPATHY: A RANDOMIZED CONTROLLED CROSSOVER STUDY.
Bousquet E; Beydoun T; Rothschild PR; Bergin C; Zhao M; Batista R; Brandely ML; Couraud B; Farman N; Gaudric A; Chast F; Behar-Cohen F
Retina; 2015 Dec; 35(12):2505-15. PubMed ID: 26017871
[TBL] [Abstract][Full Text] [Related]
19. MINERALOCORTICOID RECEPTOR ANTAGONIST TREATMENT IN BILATERAL CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: A COMPARATIVE STUDY OF EXUDATIVE AND NONEXUDATIVE FELLOW EYES.
Gergely R; Kovács I; Schneider M; Resch M; Papp A; Récsán Z; Nagy ZZ; Ecsedy M
Retina; 2017 Jun; 37(6):1084-1091. PubMed ID: 27627749
[TBL] [Abstract][Full Text] [Related]
20. Central serous chorioretinopathy treatment with spironolactone: a challenge-rechallenge case.
Ryan EH; Pulido CM
Retin Cases Brief Rep; 2015; 9(3):235-8. PubMed ID: 25790318
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]